% | $
Quotes you view appear here for quick access.

Starbucks Corporation Message Board

antisense_science 21 posts  |  Last Activity: Mar 29, 2015 1:51 PM Member since: Oct 24, 2003
  • FDA is known to mess around with PSDV in the past, the corrupt organization waited to give approval to Ilveien until they could approve alternate treatment options even those which were inferior.

    Any opinions?

  • antisense_science by antisense_science Mar 18, 2015 8:08 AM Flag

    PSDV is/was expected to meet FDA about PIII trial requirements. Any updates from Mgmt?

  • Reply to

    The Wait Will Continue.....

    by mickmack50 Mar 16, 2015 5:47 PM
    antisense_science antisense_science Mar 16, 2015 10:08 PM Flag

    You really need to think, this Co. has done nothing but given promises (related to tethadur) for nearly 2 year, partnerships, preclinical trials etc.
    Why do you think anyone in this fast traders market going to invest money and sit on it? It is not about short sellers, it is people who are sitting and getting bored and losing money because they are not making money.
    Short sellers provide liquidity, they inflate the market cap because the shares are held long and someone buys the shorted shares. For every sale, there is a buyer which implies there is buying interest even at slightly lower prices. Shorts are hoping the drugs will fail or no positive major news event occurs, the longs are hoping major partnerships occur.
    What if after all the waiting the dumb management gives away (willingly) or is forced to accept a low ball partnership offer where there is no major upfront money and not cost sharing for PI/PII? How do you think the stock will react? Maybe the shorts are waiting for something of the sort.

    Longs often believe and blame shorts for the lack of interest in the stock, but overlook simple evident facts that stare them in their faces. Longs want to believe their analysis and thesis is right so they wait and hope and wait some more and blame the shorts for the stock not trading where they think it should. Fact is the stock is trading almost where it should. Market forces do force an equilibrium between the sellers and buyers - there is not undue selling or buying pressure on the stock so the stock languishes where it is.

    Stop blaming the shorts, if at all you should be thankful. Assuming there is a 20% short interest, it implies the market cap is not 127M it is close to 150M, implying at valuation of the Co. at 150M is justified. Be happy when more shorts enter the market - but be aware they may be right and the longs could be wrong.

  • Reply to

    Regardless of what's said in the conference call....

    by markbuti Mar 13, 2015 10:30 AM
    antisense_science antisense_science Mar 14, 2015 1:46 PM Flag

    Almost all free shares - lol

  • Raj and Co. will do everything to save face, problem is when a drug fetching you about 120-150M is lost virtually overnight and the total revenue of the Co. is approx. 160-180M you are royally funked and fubar and that is about to happen to SPPI?
    Management has not been honest with shareholders, I was a foolish long bull for many years and believed all the #$%$ put out by this team.

    Sentiment: Strong Sell

  • Reply to

    Now We Wait For Catalysts...

    by mickmack50 Mar 11, 2015 10:55 PM
    antisense_science antisense_science Mar 12, 2015 2:24 AM Flag

    Still watching the paint dry - Dry AMD is going to take a long time. I hope they announce new partnerships soon, they management is obviously too slow or there is a lack of interest in partnering.
    Unlike drug development, there is not a lot to prove as far as the technology goes - but still watching and waiting. Hiope you are right mickmack - I do hope they succeed in delivering the promise. Why we are all here, some very frustrated like me, others perennially optimistic like you.

    Sentiment: Buy

  • Reply to

    alim qtrly report looks like @#$%

    by gswkool Mar 5, 2015 12:45 PM
    antisense_science antisense_science Mar 5, 2015 7:55 PM Flag

    I get slammed for one opposing view point but that is fine.
    I understand all the arguments in favor or Iluvien - malpractice law suit is not easy to make. You ever talk to a lawyer and see how far he will go with it. MOST lawyers are after easy money, threaten a lawsuit, write a few emails, collect mediocre money.
    In order to successfully sue, you really need to make a very strong case of wrong doing. Burden of proof is on the plaintiff. It is the Dr's expert opinion based on his experience and knowledge and the available remedies and his personal opinion upon which he will chose the best course of action, if you do not agree you can protest. He will still try to convince you otherwise and you may or may not agree. You have a choice to continue the treatment with the specialist or go to another specialist.
    If you decide to stay, you are agreeing with the course of action/treatment/therapy.
    Should something go wrong, you first need to go to the Board of your State and complaint, a panel of peer experts review the case on its mertis and decide on what the recommended action may be. If they all agree there was gross negligence you may have a case. Your lawyer, insurer and you can decide what the remedy would be. Remember he has a money to hire a lawyer to defend himself - you are paying out of pocket.

    It is easy to assume you can sue someone and we get constant reminders in this country. Fact is it is extremely difficult to actually do so even in the USofA. Lawyers work for their interest more than they do the client's interest. They do not want to waste their time and money if they think the easy money is there and you are not taking it. Most of the times, the course of remedy may result in additional treatments and possibly reimbursed costs of treatment at best, the Lawyer will get his fees from the client and he will tell (forcefully) to accept the offer.

  • Reply to

    alim qtrly report looks like @#$%

    by gswkool Mar 5, 2015 12:45 PM
    antisense_science antisense_science Mar 5, 2015 2:10 PM Flag

    Have you ever considered the situation from the Prescriber's point of view?
    You inject someone once and you do not need to see them for 3 years as opposed to seeing them every other month. Medicine is a business and specialists make money with more visits not less.
    Unless the laws change so Medicare (at least, for pvt. insurers it can be a legal issue) would not pay for a higher cost to treat if a longer duration (equally effective) treatment is available I do not see how money can be made.
    Rituxan vs Zevalin both CD20 monoclonal antibodies look at the cost and efficacy data. Granted Rituxan can be used for other indications besides NHL but the Market share difference between the two is insane. Now imagine how much does an oncologist make each visit. Rituxan maintenance regiment costs $280K vs 1 time infusion of Zevalin for $28K.

    You get the idea, my belief is Specialists are greedy so better alternatives which require fewer Dr. visits will not do better.

    I am long and am hoping this management can do something with other indications and with other uses of their technology. One shot in 3 years compared to a shot every 2 months is not going to help them sell more - an ophthalmologist needs to make money. Ever wonder why your Doc writes an Rx with 3-4 refills for chronic issues like HBP, Diabetes etc? Its not like they are adjusting the dose every 3-4 months. They need to see you so they can bill you for an Rx.


  • Reply to

    alim qtrly report looks like @#$%

    by gswkool Mar 5, 2015 12:45 PM
    antisense_science antisense_science Mar 5, 2015 12:49 PM Flag

    Really? What are they doing? Sales of

  • I am wondering if any "Inflection" - did I miss it already? LOL
    Try again Paul? Sorry most investors did not share your enthusiasm the last time around or did it fall on deaf ears?
    Pl. try again - something to wake this up or better yet - wake everyone up on your board and do something for the free money you are earning every year at the cost of the shareholders.

  • Reply to

    About Oncosil and relationship with Psivida

    by terry290737 Feb 25, 2015 6:54 AM
    antisense_science antisense_science Feb 27, 2015 9:07 AM Flag

    You have no clue what you are talking about. Oncosil has no relationship with pSivida - the technology was sold for a song and the CEO danced for $100K. Stop talking about OnCoSil.

  • Reply to


    by ruraddy Feb 24, 2015 12:49 PM
    antisense_science antisense_science Feb 25, 2015 5:42 PM Flag

    Much better AIDS cocktails have basically made the drug unnecessary. Isis Pharm also had a similar drug (Vitravene) which became irrelevant. Back in those days the fight was between Vitravene and Vitrasert. I have been invested in Isis for a very long time and pSivida for about 2 years now - still watching the paint dry so to speak.
    Neither of them made significant money in the long run thanks to better drugs available for AIDS patients which helped control the immune system better avoiding the need to a surgery every 8-10 months for Vitrasert.

  • Reply to

    Oh they are moving their HQ

    by lefty_rosenthal7 Feb 12, 2015 11:32 PM
    antisense_science antisense_science Feb 13, 2015 8:28 AM Flag

    It is a good thing they are thinking of conserving money.
    What happened to the Teva partnership dissolution agreement by Jan? How much money could they squeeze out of Teva?

  • Reply to

    The Most Broad CC Ever

    by mickmack50 Feb 5, 2015 8:59 PM
    antisense_science antisense_science Feb 6, 2015 9:13 AM Flag

    Anyone know how far along is Durasert trial? Is it enrolling, completed, continuing, discontinued? Nothing on Just curious. When is PFE taking over the development if at all? What is the milestone payment if they do take over PIII? Or is PFE even interested and if not what happens to that program?
    Much hype about OA - unfortunately it is years away- nice to have but too far out for any material benefit. A steroid shot helps for about 1-3 months so how long is this pre-clinical trial going to take place before they decide it will work. I have had doubts about OA only because it is a bone-on-bone disease due to lack of cartilage or depletion. How does a nano silicon tube or structure not get crushed in the joint? I am not too excited about the opportunity, it would be nice to have but the challenges are too many. Analysts on the call never ask the tough questions so you do not get any "doubters" who can help clear the air.

  • antisense_science antisense_science Feb 5, 2015 7:30 PM Flag

    Yes, you are right aren't you? Read the Qtrly report yet Losses attributable to increased expenses and stock based compensation. I have no problems giving the employees stock options, the CEO and BOD on the other hand do get exceptional health care and other benefits, handsome salaries and they are not performing so there should be no "stock based comp. to the BOD or CEO". Still what comes out of my mouth is critical of the mgmt and it will remain so until they REALLY start to work for the shareholders interest. BOD is not for the benefit of the CEO, they are the custodians of the Co. they need to ensure the CEO is doing what is required for the shareholders and the Co. Never happens.....

    Too bad people on this board want to misread me... their loss. I am long and I have a lot at stake and am #$%$ about giving stock options to the management for not delivering. $25M in milestone payment is all they can keep repeating - it is getting old. Some one on the board is unhappy about Yahoo not showing the "actual" cash on hand - too bad yahoo does not update - does it really matter? Everyone who know the Co. knows what it has, anyone who wants to buy the stock should do some reading even if it is this silly message board. Anyone who looks at Yahoo only and stays away - good riddance. Nothing lost, if the guy does not buy 200 shares of PSDV nothing will change.

  • antisense_science antisense_science Feb 4, 2015 10:19 PM Flag

    Stock is still $4 or around so free $4 is better than nothing which is ON TOP OF HIGH SALARY, BONUSES AND OTHER PERKS. GO LICK SOME MGMT OR TOUCH YOURSELF.

  • It does not help anyone. Stick to the facts and what you know.
    Co. has decent products, and a good product pipeline (if you believe the mgmt). Cash on hand is sufficient to carry the operations through 2016 and maybe to 2017.
    Revenue from ALIM is going to continue to be substandard - you could get a surprise in 2016 Q3-Q4 possible.
    Tethadur licensing is the only hope for the investors. If the Mgmt funks that up it will be goodbye adios amigos to this stock and stock holders. Based on what the management has done to date is made false promises and not delivered, while pocketing free shares from the shareholders at every opportunity.

    So - stop the hype - wait and see what this lame horse #$%$ management does and take it from there. They like every other BOD/CEO combo listed in USA are out to rob the shareholders and employees blind, they do not care about anyone but themselves. Their freebies, position and power is all that matters to them. IR woman can only say what she can say - read between the lines when you do talk to her. There is no funking catalyst that can save the longs - stop wishing for a stupid buy out. Who would seriously want to buy this out unless Tethadur is working and near the goal line - the way these farts are operating it will be 2020 before they have (20/20) vision on possibility of bringing it to market.

  • Still think PSDV is too cheap and you are the only genius in town to figure that out?
    When a stock is cheap, it is cheap for a reason. Not every stone is a diamond in the rough and this is turning out to be worthless piece of coal.

    Hey Paul step down and take your buddies on the board with you, so the shareholders can anticipate the Mgmt to do something positive with the technology besides false promises - You Paul are an under achiever and have been over promising for a very long time - still need freebie shares for you and your buddies on the BOD? Rascals.

  • Reply to

    Will US Iluvien Launch Move The Needle

    by mickmack50 Jan 14, 2015 10:34 AM
    antisense_science antisense_science Jan 20, 2015 7:50 AM Flag

    Are you stupid? BIIB at $200 would be a great buying opportunity just as you think PSDV is at $4 - the example is to show the lack of buying interest in the stock implies no one things it is grossly undervalued at $4.
    You really think you are a genius?

  • Reply to

    Will US Iluvien Launch Move The Needle

    by mickmack50 Jan 14, 2015 10:34 AM
    antisense_science antisense_science Jan 19, 2015 2:57 PM Flag

    Let us look at some facts- this Co. has cash for 1 year? May be 2 at tops. No product likely on the market in 2 yrs. ALIM contribution is going to be negligible at best.
    Licensing deals are likely - but Mgmt is sleeping on Tethadur - the technology is overly hyped and management keeps under delivering. Issues were not brought to shareholder attention - at best the technology is delayed by 2-3 yrs. As the management who is interested in partnering and where are the licenses? Eventually the technology will be sold for a song and a prayer?
    I do not care about what you think of my credibility - I have stated the same things for nearly a year. Show me some contracts/licensing deals or $4 is too high to justify the ALIM contribution. For my credibility the St. agrees with me - the stock is at $4 for a reason- you think you are a genius to find a diamond in the rough and found this Co. unnoticed for $4? How many hedge fund and mutual funds and money managers make a living researching and investing in biotech Cos? How come no one seems to agree with you because I do not see a like of interested buyers bidding the stock up - 53K shares traded in a day at $4 implies there is no interest.
    You can confuse the lack of interest with general market conditions etc. What do you think the buying interest would be if BIIB were to trade at $200? You are joke if you think you found something no one in the world noticed.Go back and keep searching for positives about PSDV and report everything you find. In the meantime hope for the stock price to move based on what #$%$ you write here.
    For me, I will keep trying to expose Paul A and his cohourts with the hope they do something positive and/or wake up drunken investors like you and collectively demand Paul A to resign if he cannot show results in a few months. Enough is enough.

47.62-0.6250(-1.30%)Apr 17 4:00 PMEDT